13 Years of Excellence: Taiwan’s Premier Biologics Summit Driving Innovation Across Manufacturing, R&D & Clinical Trials

Dr. Chung-Yi Wu joined CHO PHARMA as Executive Vice President in 2019, bringing over 20 years of research and development experience to strengthen the scientific foundation and elevate competitiveness of CHO PHARMA. In 2022, Dr. Wu was promoted to President, CEO and elected as a member of the Board of Directors.

Prior to CHO PHARMA, Dr. Wu served as Research Professor at the Genomic Research Center, Academia Sinica. During his tenure, he published 100+ scientific papers and was granted more than 40 patents. His impressive achievement has garnered him distinguished awards, such as the “2014 American Chemical Society David Y. Gin New Investigator Award” and “Taiwan Bio-Development Foundation Lecturer Scholar Award”.

Dr. Wu obtained his Ph.D. in Applied Chemistry from National Chiao Tung University and undertook postdoctoral research at the Scripps Research Institute, mentored by Prof. Chi-Huey Wong, a preeminent academician and a pioneer in glycosciences.

Professor Yeh Ming-Kung is the Chairman of Precision Biotech and a leading expert in regenerative medicine, pharmaceutical sciences, and nanobiotechnology. He currently serves as a Joint Professor at the National Defense Medical Center and an Adjunct Professor at National Tsing Hua University. Formerly, he was the Director-General of the Taiwan Food and Drug Administration (TFDA) and has held senior roles at the Ministry of Health and Welfare, including Technical Supervisor and Executive Secretary of the National Health Insurance Committee.

With a PhD in Pharmacy from the University of Nottingham, Professor Yeh has over three decades of experience spanning cell therapy, GMP-compliant biologics manufacturing, and clinical research. His expertise includes CIK, NK, CAR-NKT, and MSC-based immunotherapies, CDMO/CMO operations, and regulatory compliance for pharmaceuticals and medical devices.

Recognised among the world’s top 2% scientists by Stanford University for six consecutive years, he also serves as an international medical advisor to Carebridge Institute (Boston) and as an editorial board member of several scientific journals. Professor Yeh continues to contribute extensively to Taiwan’s biopharmaceutical development, public health policy, and cross-strait medical collaboration.

Dr. Heidi Wang is an experienced global drug development and regulatory expert with more than 30 years of Pharmaceutical Industry and Biotech experience. With expertise in oncology, virology, immunology and other therapeutic areas, Heidi led and contributed to shaping strategy and delivering approvals for Bristol Myers Squibb Company (BMS) and now, for OBI and OBIGEN.

Importantly, Heidi’s positive leadership style and inclusive mindset helped to transform company’s culture and processes to optimise their portfolio acceleration and to bring people together. Leveraging her strengths in problem solving, risk mitigation and asking the right questions, coupled with a deep expertise in drug development, Heidi is now guiding OBI, OBIGEN and as a Board member of a Taiwan-based company and her alma mater, Fu-Jen University. She also volunteers as an advisor and mentor to individuals and multiple organisations in the US, Europe and Taiwan.

Dr. Chang Jia-Ming is the Chairman and General Manager of Vacino Biomedical Co., Ltd. He obtained his Ph.D. from the Institute of Biochemistry, National Taiwan University School of Medicine in 1996.

Dr. Chang has held various key positions in Taiwan’s biomedical and regulatory sectors, including Executive Director of the Institute of Drug Platform Technology at the Biotechnology Development Center, and advisory member of the Genetically Modified Food Review Committee under the Ministry of Health and Welfare (MOHW). He also serves on the Editorial Committee of the Chinese Pharmacopoeia of the Ministry of Health and Welfare, the Standard-setting Committee of the National Bureau of Standards, Ministry of Economic Affairs, and the TAF ISO Medical Laboratory Technical Review Committee.

In academia, Dr. Chang has contributed as an Adjunct Assistant Professor at several institutions, including the Institute of Pathology and Parasitology and the Institute of Medical Sciences at the National Defense Medical Center, as well as the Department of Applied Chemistry at National Chiao Tung University.

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University. As a principal investigator in Development Center for Biotechnology (DCB), he led several drug discovery projects especially on oncology field. These topics include Top1 inhibitor, Nek2/Hec1 inhibitor, antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). After more than 15 years, he left DCB and joined OBI Pharma as the director of Medicinal Chemistry and focusing on developing anti-Trop2 ADC. In 2022, Dr. Chuang co-founded HoneyBear Biosciences, and serve as the CEO.

Dr. Chuang is the CEO and founder of CytoArm Co., Ltd. He is also a professor at Taipei Medical University in Taiwan, where he has worked for 12 years. Dr. Chuang is a senior scientist with extensive experience in drug research and development, as well as international intellectual property (IP) strategy. He specializes in recombinant protein drug technology, tumor immunology, immune cell therapy, and autoimmune diseases.

Dr. Chuang has published over 50 SCI research papers, including several in top international journals such as Biomaterials, the Journal of Controlled Release, and the Journal of Advanced Research, all of which have an impact factor exceeding 10. Additionally, Dr. Chuang has applied for more than 20 international invention patents and has licensed 4 technologies to biotech companies.

In 2020, a team led by Dr. Chuang developed a new T cell technology platform known as Armed-T. This platform has been exclusively licensed to CytoArm Co., Ltd. The first Armed-T cell product (CTA-02) is currently applying phase I clinical trials to treat colorectal cancer in Singapore, the United States, and Taiwan.

Chris Chia-Che Tsai is the Chief Technology Officer at STEMCELL BioTech, Taiwan, with over 16 years of experience in cell therapy R&D and clinical translation. He holds a Ph.D. in Biochemical Sciences from National Taiwan University and has extensive expertise across preclinical pharmacology and toxicology, CMC development, GTP/GMP facility establishment, IND submissions (FDA, TFDA) and the execution of human clinical trials for cell therapy products.

Dr Chris is a seasoned biotech leader, having served in senior executive roles overseeing R&D, manufacturing and clinical translation. He has supported founders through company scaling, strategic development and IPO-related activities in the biotech startup ecosystem.

In addition to his industry work, Chris is an invited lecturer at National Yang Ming Chiao Tung University, where he has taught graduate-level courses on practical applications and industry development in cell and regenerative therapies since 2018.

Dr. Lin is a biomedical scientist with over 20 years of experience in life science industries, spanning medical devices, pharmaceuticals, biomaterials, and biochips. He previously served as Deputy Project Director at Taiwan’s ITRI, leading global strategic alliances. As Senior VP at Body Organ Biomedical Inc., he expanded operations across Taiwan, China, and the Netherlands, establishing sales networks and securing regulatory approvals.

He led cross-border R&D collaborations, securing a €300,000 SenterNovem grant in 2009, and successfully filed 36 patents through joint research. Earlier, he also completed Taiwan's first bone filler registration. Dr. Lin holds a Ph.D. in Bioengineering from National Taiwan University and an MBA from National Chengchi University.

Dr Vivian Meng-Wei Kuo has over 16 years of in-depth experience in scientific research, technical operations, process development and validation, CMC and cGMP compliance, as well as regulatory filing and inspection from IND to BLA. She has led teams in process development, scale-up and technology transfer for more than 20 projects across clinical phases I–III to commercial stages, ranging from lab scale to 50 L, 500 L, 2000 L and 15 000 L, including multi-site coordination. She also oversaw dossier readiness and technical report preparation for IND and BLA submissions and inspections (FDA, EU, NMPA), and managed over 18 internal and CDMO projects to achieve key milestones successfully.

Sammi Hsu is the Senior Manager and Spokesperson of Ever Supreme BioTechnology (TWSE:6712), with over 17 years of experience in cell & gene therapy, exosome platforms, and clinical development. She has led multiple FDA and TFDA IND submissions, Phase I–III trials, and successful GCP inspections, and contributed to Ever Supreme’s 2021 IPO.

Sammi oversees regulatory strategy, clinical operations and scientific communication for programmes including CAR001, the company’s mRNA-engineered allogeneic γδ T-cell CAR-T therapy for solid tumours.

Xiaofei Zhou earned his Bachelor’s degree in Biotechnology and Master’s degree in Biochemistry and Molecular Biology from the School of Life Science and Technology, University of Electronic Science and Technology of China. He joined Biocytogen’s R&D department in 2011 and later served as Director of the Gene Editing Technical Division. He is currently the Director of BioMice Product Development, overseeing the development and management of animal and cell models. His work includes generating RenMice KO models for drug discovery, developing and commercializing over 1,200 humanized and immunodeficient mouse models for preclinical drug evaluation, and managing the creation of additional disease models.

Hsing-Mao Chu received his Ph.D. degree from National Taiwan University in 2010, studying protein-ligand interactions at atomic resolution using x-ray crystallography. He joined Dr. Tse-Wen Chang’s team in the Genomics Research Center, Academia Sinica, in 2011 to study CemX on human mIgE and develop anti-CemX antibodies for depleting IgE-expressing B cell. After 2013, his work expanded to antibody engineering and bioconjugation for developing therapeutic multi-specific antibodies.  

In 2015, he joined Immunwork as Director of R&D and was promoted to Vice President of R&D in 2019. He leads a dynamic team focused on developing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and fatty acid (FA) bundle-modified peptides. Through the team’s collaborative efforts, two remarkable ultra-long-acting peptide drugs initiated their first-in-human trials in the first half of 2024. These include a FA bundle-modified GLP-1 receptor agonist and a FA bundle-modified octreotide analogue. In 2023, he became the CEO of T-E Meds, Inc., a sister company of Immunwork, dedicated to advancing ADC and ARC platforms and related products. Dr. Chu is a co-inventor on more than 90 granted patents.  

Dr. Chih-Jung Chang is currently CEO of Biomanufacturing BU of EirGenix, Inc. His responsibilities are company strategy and operation of CDMO business. He got Ph. D. degree in National Taiwan University and studied on business program in UW of Seattle Unit State. Before EirGenix he works as a director of TOT Oncology Business Unit at TTY Biopharm. He was creating business and drug development strategies for licensing and collaboration in global NCE (Specialty)/ Biologics (NBE/Biosimilars) projects. With both technical knowledge and business acumen, Dr. Chang has extensive experiences building up new biologics and specialty pipelines that fit the company’s development strategy.

In addition, Dr. Chang has extensive experiences managing international networking and relationships for value-added bridge between early to late stage drug development.

Dr. Pei-Chin Tsai, who holds a Ph.D. in Molecular Medicine from National Taiwan University, has over ten years of experience in biopharmaceutical development, project management, and personnel management, including her tenure as the Former Director of Operation at Tanvex Taiwan Biologics. Dr. Tsai specializes in the development, scale-up, and technology transfer of novel protein drugs and biosimilars, complemented by expertise in strategic evaluation.

Carlos Linn, MD is a Global Clinical Development Lead Clinician and Senior Director in Oncology at Pfizer R&D. Since 2017, he has played a central role in global clinical development, safety surveillance and medical governance across Pfizer’s oncology portfolio, spanning Phase 1 to Phase 3 studies in oncology, immuno-oncology and haematologic malignancies. He has contributed to the development of multiple investigational products and currently leads or monitors several cutting-edge programmes, including CD47 blockers, BCMA bispecific antibodies, antibody–drug conjugates, CDK inhibitors and HER2-targeted therapies.

Previously, Dr Linn served as Clinical Development Lead for Oncology at Pfizer Development China (2014–2017), overseeing China- and Asia-focused programmes for key assets such as crizotinib, palbociclib and lorlatinib across early and late-phase studies.

He earned his MD from National Yang-Ming Medical College and completed specialist training in obstetrics, gynaecology and gynaecologic oncology at Taipei Veterans General Hospital. He is a board-certified gynaecologic oncologist and has held an adjunct academic appointment at National Yang-Ming University since 2004, contributing to national oncology guidelines through TCOG and NHRI.

Dr Linn began his pharmaceutical career at Eli Lilly Taiwan before joining Pfizer in 2012, holding regional and global leadership roles across Emerging Markets, China and global development. Beyond industry, he is an active educator and speaker, delivering extensive non-corporate academic lectures and receiving multiple Best Teacher Awards from 2022 to 2025.